Transcatheter Valve Replacement: Risk Levels and Contemporary Outcomes
By: Manuel Reyes and Michael J. Reardon
Abstract
Transcatheter aortic valve replacement (TAVR) has exploded into medical care for aortic stenosis, thus changing the treatment options for patients. TAVR is currently approved for extreme-risk, high-risk, and intermediate-risk patients with symptomatic severe aortic stenosis, and randomized trials for low-risk patients are underway. This article traces the trajectory of TAVR as a viable option for higher-risk patients and examines current outcomes.
DOI: https://doi.org/10.14797/mdcj-13-3-126 | Journal eISSN: 1947-6108
Language: English
Page range: 126 - 131
Published on: Jul 1, 2017
Published by: Houston Methodist DeBakey Heart & Vascular Center
In partnership with: Paradigm Publishing Services
Keywords:
© 2017 Manuel Reyes, Michael J. Reardon, published by Houston Methodist DeBakey Heart & Vascular Center
This work is licensed under the Creative Commons Attribution-NonCommercial 4.0 License.